Upstream Bio UPB
NASDAQ UPB
$6.01 -0.07 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Upstream Bio (UPB) Other Non-Current Liabilities (2023)

Upstream Bio (UPB) posted quarterly Other Non-Current Liabilities of $2.9 million for Q4 2023.

Analysis

Upstream Bio (UPB) Other Non-Current Liabilities (2023) Analysis & Trends

Upstream Bio's Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $2.9 million for Q4 2023.

  • In Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $2.9 million; the TTM figure through Dec 2023 stood at $2.9 million (changed N/A YoY), while the FY2023 annual figure was $2.9 million, changed N/A from the prior year.
  • Other Non-Current Liabilities for Q4 2023 stood at $2.9 million.
  • The five-year high for Other Non-Current Liabilities was $2.9 million in Q4 2023, with the low at $2.9 million in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Upstream Bio 327.95 Mn 327.95 Mn -3.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 2.87 Mn